



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |   |   |
|--|--|---|---|
| (51) International Patent Classification <sup>4</sup> :<br>C07K 3/20, 9/00, A61K 37/24   |  | A1  | (11) International Publication Number: WO 86/ 07594<br>(43) International Publication Date: 31 December 1986 (31.12.86) |
| (21) International Application Number: PCT/US86/01342<br>(22) International Filing Date: 20 June 1986 (20.06.86)<br>(31) Priority Application Numbers: 747,119<br>872,152<br>(32) Priority Dates: 20 June 1985 (20.06.85)<br>13 June 1986 (13.06.86)<br>(33) Priority Country: US<br>(71) Applicant: KIRIN-AMGEN, INC. [US/US]; 1900 Oak Terrace Lane, Thousand Oaks, CA 91320 (US).<br>(72) Inventors: POR-HSIUNG, Lai ; 4306 Crownfield Court, Westlake Village, CA 91361 (US). STRICKLAND, Thomas, Wayne ; 304 Fox Street, Ojai, CA 93023 (US).   |  | (74) Agent: BORUN, Michael, F.; Marshall, O'Toole, Gerstein, Two First National Plaza, Chicago, IL 60603 (US).<br>(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).<br>Published<br>With international search report. |   |
| (54) Title: PROTEIN PURIFICATION   |  |   |   |
| (57) Abstract  |  |   |   |
| <p>Chromatographic procedures are individually and jointly applied to the rapid and efficient isolation of biologically active proteins and especially glycoproteins such as recombinant erythropoietin present in the medium of growth of genetically transformed mammalian host cells. Illustratively, recombinant EPO is isolated from culture fluids by reverse phase chromatography employing a C<sub>4</sub> or C<sub>6</sub> column and elution with ethanol. Recombinant erythropoietin may also be purified by anion exchange chromatography employing, e.g., a DEAE resin, with preliminary selective elution of contaminant materials having a lower pK<sub>a</sub> than erythropoietin from the resin under conditions mitigating against acid activated protease degradation. Practiced serially, the two chromatographic procedures allow for high yields of biologically active recombinant erythropoietin from mammalian cell culture media.</p> |  |   |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                              |    |  |    |                          |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria                      | GA | Gabon                                    | MR | Mauritania               |
| AU | Australia                    | GB | United Kingdom                           | MW | Malawi                   |
| BB | Barbados                     | HU | Hungary                                  | NL | Netherlands              |
| BE | Belgium                      | IT | Italy                                    | NO | Norway                   |
| BG | Bulgaria                     | JP | Japan                                    | RO | Romania                  |
| BR | Brazil                       | KP | Democratic People's Republic<br>of Korea | SD | Sudan                    |
| CF | Central African Republic     | KR | Republic of Korea                        | SE | Sweden                   |
| CG | Congo                        | LI | Liechtenstein                            | SN | Senegal                  |
| CH | Switzerland                  | LK | Sri Lanka                                | SU | Soviet Union             |
| CM | Cameroon                     | LU | Luxembourg                               | TD | Chad                     |
| DE | Germany, Federal Republic of | MC | Monaco                                   | TG | Togo                     |
| DK | Denmark                      | MG | Madagascar                               | US | United States of America |
| FI | Finland                      | ML | Mali                                     |    |                          |
| FR | France                       |    |  |    |                          |

- 1 -

**"PROTEIN PURIFICATION"**

This application is a continuation-in-past  
5 application of application S.N. 06/747,119, filed June  
20, 1985.

**BACKGROUND**

10

The present invention relates generally to  
protein purification employing chromatographic  
techniques. More particularly, the present invention  
relates to procedures for the rapid and efficient iso-  
15 lation of biologically active proteins such as glyco-  
proteins and especially glycoproteins having high sialic  
acid content (e.g., erythropoietic factors such as  
erythropoietin) from natural (e.g., blood fractions and  
urine) and recombinant (e.g., genetically transformed  
20 mammalian cell culture fluid) sources.

Numerous techniques have in the past been  
applied in preparative separations of biochemically  
significant materials. Commonly employed preparative  
separatory techniques include: ultrafiltration, column  
25 electrofocusing, flat-bed electrofocusing, gel  
filtration, electrophoresis, isotachophoresis and  
various forms of chromatography. Among the commonly  
employed chromatographic techniques are ion exchange  
chromatography and adsorption chromatography. The  
30 former process is a separatory method wherein fluid com-  
ponents with differing net charges are distinguished and  
isolated by means of elution (stepwise or with a contin-  
uously applied gradient) with eluents of differing ionic  
strength. A gel matrix (resin) carrying either a posi-  
35 tive or negative charge is employed to adsorb (bind)  
components of opposing net charge. During desorption  
(elution) charged sample components are exchanged by

- 2 -

salt ions in the selected eluent, with specific sample components eluting at specific ionic strengths. Reverse phase adsorption chromatography involves separation of fluid sample components based on differing polarity. Sample components are adsorbed to a granulated gel matrix (resin) by non-covalent bonds. Thereafter, step-wise or continuous gradient elution results in selective desorption of components upon exchange with a non-polar solvent in the eluent.

While the numerous separatory techniques mentioned above are routinely employed in the separation of relatively small hydrophobic and hydrophylic molecules, they have somewhat limited applicability in preparative separations of relatively large molecules such as proteins, especially complex proteins such as lipoproteins, nucleoproteins and glycoproteins. Illustrative of the state of the art in protein separations are reviews by Brown, et al., Analytical Biochemistry, 99, 1-21 (1979) and Rubinstein, Analytical Biochemistry, 99, 1-7 (1979). See also, "VYDAC Comprehensive Guide to Reverse Phase Materials for HPLC", The Sep/A/Ra/Tions Groups, Hesperia, CA. and the publication of co-applicant Strickland and co-workers in Parsons, et al., Endocrinology, 114, (6), 2223-2227 (1984). Further, to the extent that, for example, reverse phase HPLC procedures have been suggested or employed in isolations of proteins or polypeptides, non-polar solvents generally recommended have included reagents that are difficult to handle or to separate from the desired protein such as acetonitrile. See Parsons, et al., supra. Only a single reference is known to exist disclosing elution with ethanol, specifically aqueous ethanol/formic acid mixtures. See Takagaki, et al. Journal of Biological Chemistry, 5, (4), 1536-1541 (1980).

The apparent limited utility of the above-noted techniques in preparatory separations of high

- 3 -

molecular weight complex proteins is especially problematic in view of recent intensive efforts directed toward isolation, purification and application to therapeutic, immunoprophylactic and diagnostic procedures of a wide variety of complex viral and eucaryotic proteins available in only minute quantities from natural sources wherein they are found in association with myriad other complex proteins. As one example, biochemically significant mammalian hematopoietic factors such as erythropoietin, thrombopoietin, granulopoietin and granulocyte-macrophage colony stimulating factor are available in extremely small quantities from urine of aplastic anemia patients. Recovery procedures from urinary fluid sources have generally been very complex, costly and labor-intensive and have generated relatively low yields of active product. A widely practiced method for obtaining biologically active preparations of urinary erythropoietin (a high molecular weight, high sialic acid content glycoprotein) may be found in Miyake, et al., Journal of Biological Chemistry, 252 (15), 5558-5564 (1977). The seven-step procedure includes ion exchange chromatography, ethanol precipitation, gel filtration, and adsorption chromatography and is reported to provide a 21% yield of glycoprotein with 70,400 Units/mg potency.

The extensive application of recombinant methodologies to the large scale preparation of eucaryotic proteins has substantially enhanced the prospects for obtaining the desired molecules in quantity and in some instances even simplified purification procedures needed to obtain biologically active materials. Illustratively, where the desired recombinant proteins need not be glycosylated to possess biological activity, large quantities of protein can often be produced in E.coli recombinant hosts in the form of

- 4 -

insoluble "inclusion bodies" which contain few protein-  
aceous contaminants, proteases, or the like. Where  
glycosylation and/or host membrane processing to develop  
proper secondary and tertiary conformation are required  
for biological activity, however, eucaryotic hosts such  
as yeast and mammalian cells in culture (e.g., COS-1 and  
CHO cells) provide more suitable recombinant hosts. Use  
of such hosts, however, generally gives rise to  
increased difficulty in recovery of biologically active  
forms of proteins in good yield. Host cell lysates  
frequently include proteinaceous constituents of suffi-  
ciently similar molecular weight, charge, polarity and  
solubility characteristics (vis-a-vis the recombinant  
protein) to make ready separation difficult. Further  
proteolytic enzymes endogenous to the host provide a  
relatively chronic source of biological activity loss  
for the desired protein. Where recombinant products are  
secreted into media supernatants by the host cells,  
similar problems attend isolation from, e.g., culture  
media from growth of transformed mammalian cell cultures  
owing principally to the complexity of the media  
employed.

There thus continues to exist a need in the  
art for rapid and efficient preparative separatory pro-  
cedures suitable for recovery of biologically active  
proteins from fluid sources and most especially for  
recovery of complex recombinant proteins such as recom-  
binant erythropoietin from variously "contaminated"  
fluids such as mammalian cell culture supernatants.

The disclosures of co-owned, co-pending U.S.  
Patent Application Serial No. 675,298, entitled "Produc-  
tion of Erythropoietin", filed November 30, 1984, by Fu-  
Kuen Lin (corresponding to PCT US84/02021, filed  
December 11, 1984, scheduled for publication June 20,  
1985 as WO85/02610) are specifically incorporated by

- 5 -

reference herein for the purpose of relating the background of the present invention, especially with respect to the state of the art regarding recombinant methodologies applied to large scale production of mammalian erythropoietin.

#### BRIEF SUMMARY

The present invention provides novel chromatographic separatory procedures individually and jointly suitable for use in the isolation of proteins and specifically applicable to the isolation of erythropoietin, especially recombinant erythropoietin, in biologically active form from fluids, especially mammalian host cell culture supernatants.

According to one of its aspects, the present invention provides for the rapid and efficient recovery of erythropoietin from a fluid by means of a reverse phase liquid chromatographic separation involving selective binding of the desired compound to a  $C_4$  or  $C_6$  resin followed by elution with aqueous ethanol in about 50 to 80 percent solution at a pH of from about 4.5 to 8.0. In a highly preferred mode of practice of this aspect of the invention, high yields of biologically active recombinant erythropoietin are recovered from mammalian host cell culture supernatants through use of a  $C_4$  resin and elution at pH 7.0 employing, stepwise or with a continuous gradient, an eluent comprising about 60 percent aqueous ethanol. Culture supernatants are preferably concentrated before chromatographic treatment and suitable steps are taken to remove ethanol from collected eluent fractions containing erythropoietin. The above elegantly simply separatory procedure reproducibly allows for isolation of erythropoietin having high specific activity in yields approaching 50 percent or more.

- 6 -

In another of its aspects, the present invention provides for rapid and efficient recovery of erythropoietin from a fluid by means of anion exchange chromatography involving selective binding of erythropoietin to a selected cationic resin, treatment of bound materials to guard against acid activation of proteases present, selective elution of bound materials having pKa's greater than that of erythropoietin with aqueous acid at pH's of from about 4.0 to about 6.0, and then elution with aqueous salt at about pH 7.0. Erythropoietin-containing eluent fractions are enriched with biologically active material but may optionally be subject to further processing, e.g., by gel filtration upon ethanol removal. In a presently highly preferred mode of practice of this aspect of the invention, high yields of biologically active recombinant erythropoietin are recovered from mammalian host cell culture supernatants through anion exchange chromatography employing a DEAE agarose resin. Following loading of the DEAE column, urea is added to protect against subsequent acid activation of proteases present and bound fluid components having pKa's greater than erythropoietin are eluted by washings with aqueous acid at about pH 4.3. Thereafter, the pH is adjusted to about 7.0 and aqueous salt is applied stepwise or in a continuous gradient to selectively elute biologically active erythropoietin.

In still another of its aspects, the invention provides for an erythropoietin recovery procedure involving serial application of the ion exchange and reverse phase liquid chromatographic procedures previously described. More specifically, erythropoietin (especially recombinant erythropoietin) is recovered from a fluid (such as a mammalian host cell culture supernatant) in the following stepwise manner. Culture supernatant pools (preferably preliminarily diafiltered and concentrated) are loaded on an ionic exchange column



- 7 -

at about pH 7.0 and erythropoietin selectively binds to the cationic resin (preferably DEAE agarose). Bound materials are stabilized against acid activated protease degradation (preferably by addition of urea) and bound materials having pKa's greater than erythropoietin are eluted by one or more aqueous acid washed at from about pH 4.0 to pH 6.0 (preferably about pH 4.3). Thereafter, biologically active erythropoietin is eluted with aqueous salt at about pH 7.0. The erythropoietin-containing eluent fractions are then subjected to reverse phase liquid chromatography on a C<sub>6</sub> or, preferably, C<sub>4</sub> resin to selectively bind erythropoietin. Bound biologically active erythropoietin is then eluted at from about pH 4.5 to about pH 8.0 (preferably about pH 7.0) with an aqueous ethanol solution of from about 50 to 80 (preferably about 60) percent. The desired erythropoietin is isolated within erythropoietin-containing eluent fractions (as determined by absorbance at 280 nm. Ethanol may then be removed and the product may be subjected to gel filtration (e.g., using a Sephacryl S-200 column) with development using, e.g., a pharmaceutical formulation buffer such as 20 mm sodium citrate/100 mm sodium chloride, pH 6.8 to 7.0.

Other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description of the practice of preferred embodiments thereof.

30

#### DETAILED DESCRIPTION

Practice of the present invention is believed to be suitably illustrated by the following examples practiced on pooled CHO cell supernatants prepared in the manner described in Example 10 of the aforementioned U.S. Patent Application Serial No. 675,298. More specifically, the treated supernatants were derived from cell

- 8 -

strain CHO pDSVL-gHuEPO "amplified" by means of MTX and grown in roller bottles in serum-free medium as described at page 62 of the application. Example 1  
5 generally refers to recovery of biologically active recombinant human erythropoietin by means of a reverse phase liquid chromatography. Example 2 relates to a composite recovery procedure practiced on the same supernatant material. Example 3 relates to RIA and in  
10 vivo assays performed on the resulting purified materials.

#### EXAMPLE 1

15 Unconcentrated culture supernatant obtained by pooling first and second (7-day) cycle supernatants was loaded on a closed (high pressure configuration) column laboratory packed with C<sub>4</sub> matrix (VYDAC 214TP-B). A  
0.45 x 10 mm column was employed with a flowrate of 1  
20 ml/min. Following sample application, biologically active recombinant erythropoietin was eluted with a linear gradient from 10 mM Tris, pH 7.0 to 80% EtOH/10 mM Tris, pH 7.0. Protein concentration was UV-monitored at 230 nm and the fractions of eluent at about  
25 60% EtOH were pooled.

#### EXAMPLE 2

The composite recovery procedure of this example consisted of serial practice of ion exchange and  
30 reverse phase chromatographic procedures performed on a larger fraction of supernatant than in Example 1. The chromatographic procedures were preceded by concentration and diafiltration steps and followed by a gel filtration processing step.

35

- 9 -

### 1. Concentration and Diafiltration

First and second (7-day) growth cycle supernatants were separately concentrated thirty-fold using a Pellicon ultrafiltration device (Millipore, Bedford, Mass.) with a 10,000 MW cutoff. Concentrated first and second cycle media were pooled and diafiltered on the Pellicon device against 10 mM Tris at about pH 7.0. (The diafiltered media may optionally be made 20  $\mu$ M in  $\text{CuSO}_4$  before ion exchange chromatography.) It may be noted that any ultrafiltration device with a 10,000 or 30,000 MW cutoff may be used and that the diafiltration step may be performed against any suitable low ionic strength buffer at a pH of from about 6.0 to 8.5.

### 2. Ion Exchange Chromatography

The concentrated, diafiltered media from step 1 was pumped on a relatively low density DEAE agarose column (Bio-Rad, Richmond, CA.). The column was then washed with about four volumes of 5 mM acetic acid/1 mM glycine/6M urea at about pH 4.5. Optionally, the wash may include 20  $\mu$ M  $\text{CuSO}_4$  to assist in oxidation of sulfhydryl groups on the undesired protein. Glycine was incorporated to react with any cyanate present. Urea serves to stabilize against acid activation of proteases at low pH and to assist in solubilization of proteins. Following the washings which serve to elute off bound materials with greater pKa's than erythropoietin, the column was washed with 25 mM NaCl/10 mM Tris at about pH 7.0 to return to neutral pH and remove urea. Biologically active erythropoietin was eluted with 75 mM NaCl/10 mM Tris at about pH 7.0.  $\text{CuSO}_4$  (20  $\mu$ M) can optionally be included in both the neutralizing wash and/or the elution step.

35

- 10 -

### 3. Reverse Phase Chromatography

The procedure applied was essentially as in Example 1 except that an open column, low pressure mode was employed. If copper sulfate was employed in the buffers in step 2 above, the erythropoietin fraction was made 1mm in EDTA before loading to the reverse phase column in order to facilitate removal of copper. Following identification of the erythropoietin "peak" in gradient fractions at about 60% ethanol, it is preferred to dilute the collected fraction(s) five-fold with, e.g., 10 mm TRIS at pH 7.0 to reduce ethanol concentration and facilitate ethanol removal. Ethanol was removed by binding the erythropoietin to DEAE column and eluting with a small amount of buffer (20 mm sodium citrate/100 mm sodium chloride).

### 4. Gel Filtration

Products of step 3 from which ethanol has been removed was loaded on a column of Sephacryl S-200 (Pharmacia, Piscataway, N.J.). The column was developed using a projected pharmaceutical formulation buffer of 20 mm sodium citrate/100 mm sodium chloride at pH 6.8 to 7.0.

### EXAMPLE 3

Radioimmunoassay and in vivo bioassay procedures as described in the above-mentioned U.S. Patent Application Serial No. 675,298 were performed using the recombinant erythropoietin recovered by the procedures of Example 1 and 2. The experimental data indicated yields of 52 and 16 percent, respectively, for the Example 1 and 2 products, with ratios of in vivo to RIA activity of 1.02 and 1.3. Subsequent repeats of the Example 2 procedure on different supernatants have provided yields on the order of 30-50 percent.

- 11 -

The purity of the erythropoietin after the purification steps of the present invention is at least about 95% and generally greater than about 98%. The  
5 purity of the recombinant erythropoietin was determined by non-reducing SDS-PAGE analysis, reducing SDS-PAGE analysis and high pressure liquid chromatography gel  
10 filtration. The highly pure compositions of the present invention contain less than 0.5% Chinese hamster ovary cell (CHO) and bovine serum proteins as determined by an  
ELISA assay. The recombinant erythropoietin purified in accordance with the methods of the present invention has a substantially greater specific activity than erythro-  
15 poietin previously obtained utilizing other purification techniques. In addition, the purified recombinant erythropoietin compositions of the present invention contain less than 2.5 EU/ml pyrogens as determined by  
limulus amebocyte assay.. Furthermore, the purified com-  
20 positions of the present invention contain less than 10 pg DNA/10,000 units of DNA contamination as measured by dot blot analysis.

The highly purified recombinant erythropoietin compositions provide a pharmaceutically acceptable composition wherein undesired proteins are removed. The  
25 removal of undesired proteins from recombinant erythropoietin in accordance with the method of the present invention provides a purified composition which results in reduced immunological responses, i.e. anaphylaxis, when used to treat humans. In addition, the removal of  
30 the undesired proteins may increase the stability of the recombinant erythropoietin composition by preventing degradation of the recombinant erythropoietin by contaminating hydrolytic enzymes.

While the foregoing illustrative examples have  
35 described procedures of the invention as practiced for recovery of erythropoietin from mammalian cell culture sources, the procedures are believed to be suitable for

- 12 -

recoveries practiced on other culture fluids such as mammalian lysate/supernatant combination and similar fluids derived from yeast cell cultures. Similarly, the individual and composite procedures (and especially the ion exchange chromatographic procedures) are expected to be useful in recovery of erythropoietin from natural sources such as urine.

It will be apparent to those skilled in the art that the procedures above applied to recovery of erythropoietin can be expected to find applicability in recovery of other complex proteins, especially glycoproteins produced by recombinant methodologies. Glycoproteins whose recovery is within the contemplation of the invention include such distinct products as recombinant tissue plasminogen activator, Factor VIII and Herpes Simplex Virus Glycoprotein D.

20

25

30

35

## WHAT IS CLAIMED IS:

1. A process for the efficient recovery of erythropoietin in biologically active form from a fluid, said process comprising the steps of:

subjecting said fluid to reverse phase liquid chromatographic separation involving an immobilized C<sub>4</sub> or C<sub>6</sub> resin, thereby to selectively bind erythropoietin in said fluid to said resin;

selectively eluting bound erythropoietin from said resin with an aqueous ethanol solution of from 50 to 80 percent at a pH of from about 4.5 to about 8.0; and,

isolating erythropoietin-containing fractions of the eluent.

2. The process of claim 1 applied to recovery of recombinant erythropoietin from a cell culture derived fluid.

3. The process of claim 2 applied to recovery of erythropoietin from a mammalian cell culture derived fluid.

4. The process of claim 3 applied to recovery of erythropoietin from a mammalian cell culture supernatant.

5. The process of claim 1 applied to recovery of erythropoietin urinary fluids.

6. The process of claim 1 wherein the resin is a C<sub>4</sub> resin.

7. The process of claim 1 wherein said elution step is carried out at about pH 7.0.

- 14 -

8. The process of claim 1 wherein said elution step is carried out continuously by means of a linear aqueous ethanol gradient.

9. The process of claim 8 wherein erythropoietin is isolated with the elution fraction or fractions comprehending aqueous ethanol eluent solutions of about 60 percent.

10. The process of claim 1 further including the step of removal of ethanol from isolated erythropoietin-containing eluent fractions.

11. A process for the efficient recovery of erythropoietin from a fluid, said process comprising the following steps in sequence:

subjecting the fluid to ion exchange chromatographic separation at about pH 7.0, thereby to selectively bind erythropoietin in said sample to a cationic resin;

stabilizing materials bound to said resin against degradation by acid activated proteases;

selectively eluting bound contaminant materials having a pKa greater than that of erythropoietin by treatment with aqueous acid at a pH of from about 4.0 to 6.0; and

selectively eluting erythropoietin by treatment with an aqueous salt at a pH of about 7.0; and isolating erythropoietin-containing eluent fractions.

12. The process of claim 11 applied to recovery of recombinant erythropoietin from a cell culture derived fluid.



- 15 -

13. The process of claim 12 applied to recovery of erythropoietin from a mammalian cell culture derived fluid.

14. The process of claim 13 applied to recovery of erythropoietin from a mammalian cell culture supernatant.

15. The process of claim 11 applied to recovery of erythropoietin from urinary fluids.

16. The process of claim 11 wherein the cationic resin is a DEAE agarose resin.

17. The process of claim 11 wherein said stabilizing step comprises treatment with urea.

18. A process for the efficient recovery of erythropoietin from a fluid, said process comprising the following steps in sequence:

(1) subjecting the fluid to ion exchange chromatographic separation at about pH 7.0, thereby to selectively bind erythropoietin in said sample to a cationic resin;

(2) stabilizing materials bound to said resin against degradation by acid activated proteases;

(3) selectively eluting bound contaminant materials having a pKa greater than that of erythropoietin by treatment with aqueous acid at a pH of from about 4.0 to 6.0;

(4) selectively eluting erythropoietin by treatment with an aqueous salt at a pH of about 7.0;

(5) subjecting eluted, erythropoietin-containing fluids to reverse phase liquid chromatographic separation involving an immobilized C<sub>4</sub> or C<sub>6</sub> resin, thereby to selectively bind erythropoietin in said fluid to said resin;

- 16 -

(6) selectively eluting bound erythropoietin from said resin with an aqueous ethanol solution of from 50 to 80 percent at a pH of from about 4.5 to about 8.0; and,

(7) isolating erythropoietin-containing fractions of the eluent.

19. The process of claim 18 applied to recovery of recombinant erythropoietin from a cell culture derived fluid.

20. A process for the efficient recovery of recombinant erythropoietin from a mammalian cell culture supernatant fluid, said process comprising the following steps in sequence:

(1) subjecting the fluid to ion exchange chromatographic separation at about pH 7.0, thereby to selectively bind erythropoietin in said sample to a DEAE agarose cationic resin;

(2) stabilizing materials bound to said resin against degradation by acid activated proteases through treatment with urea;

(3) selectively eluting bound materials having a pKa greater than that of erythropoietin by treatment with aqueous acid at a pH of about 4.3.

(4) selectively eluting erythropoietin by treatment with an aqueous salt at a pH of about 7.0;

(5) subjecting erythropoietin-containing eluent fractions to reverse phase liquid chromatographic separation involving an immobilized C<sub>4</sub> resin, thereby to selectively bind erythropoietin in said fluid to said resin;

(6) selectively eluting bound erythropoietin from said resin with an aqueous ethanol solution of about 60 percent at a pH of about 7.0; and,

- 17 -

(7) isolating erythropoietin-containing fractions of the eluent.

21. The process of claim 20 further including the step of removal of ethanol from isolated erythropoietin-containing fractions.

22. A purified recombinant erythropoietin composition having an erythropoietin content of at least about 95% as determined by non-reducing SDS-PAGE analysis.

23. A purified recombinant erythropoietin composition of Claim 22 wherein the erythropoietin content is greater than about 98% as determined by non-reducing SDS-PAGE analysis.

24. A purified recombinant erythropoietin composition of Claim 22 having less than 0.5% CHO and bovine serum proteins.

25. A purified recombinant erythropoietin composition of Claim 23 having less than 0.5% CHO and bovine serum proteins.

26. A purified recombinant erythropoietin composition having an erythropoietin content of at least about 95%, having less than 0.5% CHO and bovine serum proteins, having less than 2.5 EU/ml pyrogens, and having less than 10 pg DNA/10,000 units.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US86/01342

|  |  |                                     |
|--|--|-------------------------------------|
| <b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>3</sup>  |  |                                     |
| According to International Patent Classification (IPC) or to both National Classification and IPC  |  |                                     |
| IPC(4) C07K 3/20, 9/00; A61K 37/24   |  |                                     |
| U.S. CL. 424/95,99,101; 435/68,172.2,172.3,240,241; 514/6  |  |                                     |
| <b>II. FIELDS SEARCHED</b>   |  |                                     |
| Minimum Documentation Searched <sup>4</sup>  |  |                                     |
| Classification System  | Classification Symbols   |                                     |
| U.S.   | 424/95,99,101; 435/68,172.2,172.3,240,241<br>514/6; 530/380,397,399,417.   |                                     |
| Documentation Searched other than Minimum Documentation<br>to the Extent that such Documents are Included in the Fields Searched <sup>5</sup>  |  |                                     |
| <b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup>  |  |                                     |
| Category <sup>6</sup>  | Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>   | Relevant to Claim No. <sup>18</sup> |
| Y  | US,A, 4,289,690 (PESTKA) Published<br>15 SEPTEMBER 1981.   | 1-10,18-21                          |
| Y  | US,A, 4,303,650 (TAKEZAWA) Published<br>01 DECEMBER 1981.  | 1-10,18-21                          |
| X  | US,A, 4,465,624 (CHIBA) Published<br>14 AUGUST 1984.   | 22-26                               |
| X,P  | US,A, 4,558,005 (GOLDWASSER) Published<br>10 DECEMBER 1985.  | 22-26                               |
| Y  | Advances in Chromatography, <u>20</u> (1982) P. 43<br>GIDDINGS, Editor.  | 1-10,18-21                          |
| Y  | J. Biol. Chem. <u>225</u> No.4 (1980) pp. 1536-41.<br>TAKAGAKI.  | 1-10,18-21                          |
| Y  | Analytical Biochemistry, <u>99</u> , 1-21 (1979)<br>BROWN.   | 1-10,18-21                          |
| Y  | High Performance Liquid Chromatography of<br>Proteins, Peptides, Proceedings of the 1st.<br>Int. Symposium (1981), HERN, Editor.<br>pp. 161-165. O'HARE. | 1-10,18-21                          |
| <p><sup>15</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> |  |                                     |
| <b>IV. CERTIFICATION</b>   |  |                                     |
| Date of the Actual Completion of the International Search <sup>1</sup>   | Date of Mailing of this International Search Report <sup>2</sup>   |                                     |
| 30 JULY 1986   | 02 SEP 1986  |                                     |
| International Searching Authority <sup>1</sup>   | Signature of Authorized Officer <sup>19</sup>  |                                     |
| ISA/US   | Howard E. Schain<br>HOWARD E. SCHAIN   |                                     |

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

| Category * | Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup> | Relevant to Claim No <sup>18</sup> |
|------------|--|------------------------------------|
| X          | Proc. Natl. Acad. Sch. USA. <u>81</u> (1984)<br>pp. 2708-2712. LEE-HUANG.                                      | 22-26                              |
| X,P        | US,A, 4,568,488 (LEE-HUANG) Published<br>04 FEBRUARY 1986.   | 22-26                              |